HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Increase in cellular cyclic AMP concentrations reverses the profibrogenic phenotype of cardiac myofibroblasts: a novel therapeutic approach for cardiac fibrosis.

Abstract
Tissue fibrosis is characterized by excessive production, deposition, and contraction of the extracellular matrix (ECM). The second messenger cAMP has antifibrotic effects in fibroblasts from several tissues, including cardiac fibroblasts (CFs). Increased cellular cAMP levels can prevent the transformation of CFs into profibrogenic myofibroblasts, a critical step that precedes increased ECM deposition and tissue fibrosis. Here we tested two hypotheses: 1) myofibroblasts have a decreased ability to accumulate cAMP in response to G protein-coupled receptor (GPCR) agonists, and 2) increasing cAMP will not only prevent, but also reverse, the myofibroblast phenotype. We found that myofibroblasts produce less cAMP in response to GPCR agonists or forskolin and have decreased expression of several adenylyl cyclase (AC) isoforms and increased expression of multiple cyclic nucleotide phosphodiesterases (PDEs). Furthermore, we found that forskolin-promoted increases in cAMP or N(6)-phenyladenosine-cAMP, a protein kinase A-selective analog, reverse the myofibroblast phenotype, as assessed by the expression of collagen Iα1, α-smooth muscle actin, plasminogen activator inhibitor-1, and cellular contractile abilities, all hallmarks of a fibrogenic state. These results indicate that: 1) altered expression of AC and PDE isoforms yield a decrease in cAMP concentrations of cardiac myofibroblasts (relative to CFs) that likely contributes to their profibrotic state, and 2) approaches to increase cAMP concentrations not only prevent fibroblast-to-myofibroblast transformation but also can reverse the profibrotic myofibroblastic phenotype. We conclude that therapeutic strategies designed to enhance cellular cAMP concentrations in CFs may provide a means to reverse excessive scar formation following injury and to treat cardiac fibrosis.
AuthorsDavid Lu, Nakon Aroonsakool, Utako Yokoyama, Hemal H Patel, Paul A Insel
JournalMolecular pharmacology (Mol Pharmacol) Vol. 84 Issue 6 Pg. 787-93 (Dec 2013) ISSN: 1521-0111 [Electronic] United States
PMID24085841 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Actins
  • Isoenzymes
  • Plasminogen Activator Inhibitor 1
  • Receptors, G-Protein-Coupled
  • smooth muscle actin, rat
  • Colforsin
  • Collagen
  • Cyclic AMP
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Adenylyl Cyclases
Topics
  • 3',5'-Cyclic-AMP Phosphodiesterases (metabolism)
  • Actins (metabolism)
  • Adenylyl Cyclases (metabolism)
  • Animals
  • Cells, Cultured
  • Colforsin (pharmacology)
  • Collagen (biosynthesis)
  • Cyclic AMP (biosynthesis)
  • Fibroblasts (cytology, metabolism)
  • Fibrosis
  • Isoenzymes (metabolism)
  • Male
  • Myocardium (cytology, metabolism)
  • Myofibroblasts (cytology, metabolism)
  • Plasminogen Activator Inhibitor 1 (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, G-Protein-Coupled (agonists)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: